Iadademstat is under clinical development by Oryzon Genomics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Iadademstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iadademstat overview
Iadademstat (ORY-1001) is under development for the treatment of small cell lung cancer, newly diagnosed, relapsed and refractory acute myeloid leukemia (AML) and neuroendocrine carcinoma. The drug candidate is administered orally. It is a new molecular entity (NME). The drug candidate targets lysine specific demethylase-1 (LSD1, aka KDM1). It is developed based on epigenetic platform. It was also under development for solid tumors like prostate cancer and breast cancer.
Oryzon Genomics overview
Oryzon Genomics (Oryzon) is a clinical-stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company provides epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Oryzon clinical-stage products include ORY-1001, an oncology product for treating acute leukemia disease, ORY-2001 for treating Alzheimer’s disease, Parkinson’s disease and others and ORY-3001 for treating other indications of cancer and ORY-4001 a selective HDAC6 inhibitor. It provides therapeutic programs and collaborative research services. It operates offices in Spain and the US. Oryzon is headquartered in Cornella de Llobregat, Barcelona, Spain.
For a complete picture of Iadademstat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
